The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer

OncoImmunology

Volumn 6, Issue 9, 2017, Pages

  Zhang, Yan ^a   Mei, Qian ^a   Liu, Yang ^a   Li, Xiang ^a   Brock, Malcolm V ^b   Chen, Meixia ^a   Dong, Liang ^a   Shi, Lu ^a   Wang, Yao ^a   Guo, Mingzhou ^a   Nie, Jing ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CIK therapy; decitabine; epigenetic therapy; platinum sensitivity; recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; DECITABINE; PACLITAXEL; PLATINUM;

ABDOMINAL DISTENSION; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CELL THERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DNA METHYLATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 85028563236     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1323619     Document Type: Article

References (35)

1. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy:A gynecologic oncology group study. J Clin Oncol 1994; 12:1748-53; PMID:7916038; https://doi.org/10.1200/JCO.1994.12.9.1748
2. Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol 2012; 23(Suppl 10):x128-31; PMID:22987947; https://doi.org/10.1093/annonc/mds358
3. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL, Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389-93; PMID:1999708; https://doi.org/10.1200/JCO.1991.9.3.389
4. Cannistra SA. Is there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 2002; 20:1158-60; PMID:11870154; https://doi.org/10.1200/JCO.2002.20.5.1158
5. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer:Recommendations for improving outcomes. Nat Rev Cancer 2011; 11:719-25; PMID:21941283; https://doi.org/10.1038/nrc3144
6. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-93; PMID:9196130; https://doi.org/10.1200/JCO.1997.15.6.2183
7. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma:A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-22; PMID:11454878; https://doi.org/10.1200/JCO.2001.19.14.3312
8. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29; PMID:15590954; https://doi.org/10.1056/NEJMra041842
9. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72:2197-205; PMID:22549947; https://doi.org/10.1158/0008-5472.CAN-11-3909
10. Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, Wulfridge P, Matei D, Nephew KP. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 2014; 5:3579-89; PMID:25003579; https://doi.org/10.18632/oncotarget.1961
11. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31:4567-76; PMID:22249249; https://doi.org/10.1038/onc.2011.611
12. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl JMed 2003; 348:203-13; PMID:12529460; https://doi.org/10.1056/NEJMoa020177
13. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer:A meta-analysis. Gynecol Oncol 2012; 124:192-8; PMID:22040834; https://doi.org/10.1016/j.ygyno.2011.09.039
14. Schiffmann I, Greve G, Jung M, Lubbert M. Epigenetic therapy approaches in non-small cell lung cancer:Update and perspectives. Epigenetics 2016; 11:858-70; PMID:27846368; https://doi.org/10.1080/15592294.2016.1237345
15. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012; 18:1751-9; PMID:22275504; https://doi.org/10.1158/1078-0432.CCR-11-2442
16. Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer:A phase II clinical study. Cancer Immunol Immunother 2012; 61:2125-33; PMID:22581306; https://doi.org/10.1007/s00262-012-1260-2
17. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148:1383-91 e6; PMID:25747273; https://doi.org/10.1053/j.gastro.2015.02.055
18. Kim HM, Kang JS, Lim J, Park SK, Lee K, Yoon YD, Lee CW, Lee KH, Han G, Yang KH, et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 2007; 30:1464-70; PMID:18087816; https://doi.org/10.1007/BF02977372
19. Liu J, Li H, Cao S, Zhang X, Yu J, Qi J, An X, Yu W, Ren X, Hao X. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother 2014; 37:115-22; PMID:24509174; https://doi.org/10.1097/CJI.0000000000000021
20. Rustin GJ., Can we now agree to use the same definition to measure response according to CA-125? J Clin Oncol 2004; 22:4035-6; PMID:15364965; https://doi.org/10.1200/JCO.2004.06.628
21. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011; 117:1661-9; PMID:21472713; https://doi.org/10.1002/cncr.25701
22. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21:771-5; PMID:21543939; https://doi.org/10.1097/IGC.0b013e31821bb8aa
23. Mei Q, Chen M, Lu X, Li X, Duan F, Wang M, Luo G, Han W. An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. Oncotarget 2015; 6:16698-711; PMID:25895027; https://doi.org/10.18632/oncotarget.3677
24. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18:3093-100; PMID:10963637; https://doi.org/10.1200/JCO.2000.18.17.3093
25. Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol 2013; 31:4060-6; PMID:24081946; https://doi.org/10.1200/JCO.2012.45.1278
26. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26:890-6; PMID:18281662; https://doi.org/10.1200/JCO.2007.13.6606
27. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome:A multicenter phase II study in elderly patients. J Clin Oncol 2000; 18:956-62; PMID:10694544; https://doi.org/10.1200/JCO.2000.18.5.956
28. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs 2013; 31:1257-64; PMID:23504398; https://doi.org/10.1007/s10637-013-9947-6
29. Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients:Results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer 2015; 51:352-8; PMID:25534295; https://doi.org/10.1016/j.ejca.2014.11.017
30. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 2014; 110:1923-9; PMID:24642620; https://doi.org/10.1038/bjc.2014.116
31. Hacker KE, Uppal S, Johnston C. Principles of Treatment for borderline, micropapillary serous, and low-grade ovarian cancer. J Natl Compr Canc Netw 2016; 14:1175-82; PMID:27587627; https://doi.org/10.6004/jnccn.2016.0124
32. Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012; 125:661-6; PMID:22406638; https://doi.org/10.1016/j.ygyno.2012.02.037
33. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015; 527:249-53; PMID:26503055; https://doi.org/10.1038/nature15520
34. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015; 162:961-73; PMID:26317465; https://doi.org/10.1016/j.cell.2015.07.056
35. Heninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 2015; 6:29; PMID:25699047; https://doi.org/10.3389/fimmu.2015.00029